Cephalosporins Should Be the Preferred Oral Antibiotics for Empiric Treatment of Outpatient Acute Pyelonephritis
When managing an outpatient with suspected pyelonephritis, consider switching your empiric oral antibiotic choice to a cephalosporin rather than relying on fluoroquinolones or TMP-SMX. This change aligns with current recommendations for optimizing stewardship while maintaining robust coverage. Always confirm local resistance patterns before making this switch.
This article strongly advocates for a shift in standard practice, recommending cephalosporins as the preferred oral antibiotic choice for empiric management of acute pyelonephritis treated in the outpatient setting. Given that pyelonephritis is a frequent and potentially serious ED presentation requiring prompt coverage to avert sepsis or renal injury, selecting the right oral agent while maintaining stewardship is key. Historically, fluoroquinolones and TMP-SMX have been the go-to empirical options according to existing consensus guidelines. The authors are arguing for cephalosporins as the superior alternative in this common clinical scenario.